Tema ETFs has been capitalizing on the threat appetite for weight reduction stocks.
It is dreary the GLP-1, Obesity & Cardiometabolic ETF (HRTS), which is up 26% since its inception final November.
The firm’s founder and CEO Maurits Pot thinks the profitable weight reduction alternate is no longer primarily based on honest correct hype.
“The corporations we monitor and the corporations we put money into are having a perceive no longer only correct at a weight reduction skill, but furthermore diversified approaches,” Pot urged CNBC’s “ETF Edge” on Monday. “We would possibly perchance well gape a world the attach the majority of the arena’s inhabitants takes a GLP-1, no longer only correct for weight reduction, but for diversified ailments.”
His top holdings embody Mounjaro manufacturer Eli Lilly and Ozempic and Wegovy maker Novo Nordisk. Eli Lilly is up 57% to date this twelve months, while Novo Nordisk is up 38%.
Plus, Pot does no longer seek info from the price mark for GLP-1s to discourage unique patients. He thinks they’ll reach down seriously in the following two to three years.
“We would possibly perchance well gape drug pricing reach down from $12,000 to per chance $6,000 a twelve months, so per chance $500 a month,” acknowledged Pot, who facets out insurance coverage coverage most frequently makes the treatments extra realistic to patients.
